Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11095474rdf:typepubmed:Citationlld:pubmed
pubmed-article:11095474lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0042149lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0072301lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0597298lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C1419063lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0086982lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:11095474lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:11095474pubmed:issue11lld:pubmed
pubmed-article:11095474pubmed:dateCreated2000-11-29lld:pubmed
pubmed-article:11095474pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:abstractTextPGE2 is known to induce uterine contraction by increasing intracellular Ca2+. In the present study, to investigate other functions of PGE2 in human uterus, two EP3 isoforms were isolated by the RT-PCR method using human uterus polyadenylated ribonucleic acid (RNA). These EP3 isoforms, named EP3-V and EP3-VI, are composed of 402 and 393 amino acid residues, respectively, which are unique compared with EP3 isoforms of other species. Their N-terminal 359 amino acid residues are identical to those of previously reported human EP3 isoforms, whereas the two isoforms contained a novel amino acid sequence in their C-terminal tails. The dissociation constant values of EP3-V and EP3-VI for PGE2 were 3.9 and 1.4 nmol/L, respectively, which were consistent with those of previously reported EP3 isoforms. Signaling experiments revealed that M&B28767, an EP3 agonist, not only inhibited forskolin-induced cAMP concentrations, but also activated mitogen-activated protein kinase in Chinese hamster ovary cells stably expressing EP3-V and EP3-VI. These responses were abolished by treatment with pertussis toxin. In addition, M&B28767 increased cAMP concentrations in EP3-VI-expressing cells, whereas it did not in EP3-V-expressing cells. M&B28767 did not stimulate phosphoinositide turnover in EP3-V or EP3-VI-expressing cells. EP3-V and EP3-VI messenger RNAs (mRNAs) were detected abundantly in human uterus, whereas weak, but substantial, bands were detected in the lung and kidney in RT-PCR specific for each mRNA. In situ hybridization revealed EP3-V and EP3-VI mRNAs in the human myometrium, but not in the endometrium. The present study suggests that EP3-V and EP3-VI are possibly involved in the proliferation of cells in human myometrium.lld:pubmed
pubmed-article:11095474pubmed:languageenglld:pubmed
pubmed-article:11095474pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11095474pubmed:statusMEDLINElld:pubmed
pubmed-article:11095474pubmed:monthNovlld:pubmed
pubmed-article:11095474pubmed:issn0021-972Xlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:MatsumotoTTlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:KotaniMMlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:OgawaYYlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:YamamotoYYlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:NakaiMMlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:NarumiyaSSlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:TanakaIIlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:YoshimasaYYlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:SugawaraAAlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:SagawaNNlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:MusiHHlld:pubmed
pubmed-article:11095474pubmed:authorpubmed-author:SuganamiTTlld:pubmed
pubmed-article:11095474pubmed:issnTypePrintlld:pubmed
pubmed-article:11095474pubmed:volume85lld:pubmed
pubmed-article:11095474pubmed:ownerNLMlld:pubmed
pubmed-article:11095474pubmed:authorsCompleteYlld:pubmed
pubmed-article:11095474pubmed:pagination4315-22lld:pubmed
pubmed-article:11095474pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:meshHeadingpubmed-meshheading:11095474...lld:pubmed
pubmed-article:11095474pubmed:year2000lld:pubmed
pubmed-article:11095474pubmed:articleTitleMultiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus.lld:pubmed
pubmed-article:11095474pubmed:affiliationDepartment of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Japan.lld:pubmed
pubmed-article:11095474pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11095474pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11095474pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11095474lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11095474lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11095474lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11095474lld:pubmed